These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36936405)

  • 1. Characteristics and lipid lowering treatment patterns in patients tested for lipoprotein(a): A real-world US study.
    Hu X; Cristino J; Gautam R; Mehta R; Amari D; Heo JH; Wang S; Wong ND
    Am J Prev Cardiol; 2023 Jun; 14():100476. PubMed ID: 36936405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States.
    Fonseca AF; Byrne H; Laguna A; Itani T; Studer R; Heo J; Dillon A; Ferber P; Costa-Scharplatz M
    J Manag Care Spec Pharm; 2023 May; 29(5):519-529. PubMed ID: 37121256
    [No Abstract]   [Full Text] [Related]  

  • 3. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy.
    Sciattella P; Maggioni AP; Arcangeli E; Sidelnikov E; Kahangire DA; Mennini FS
    Adv Ther; 2022 Jan; 39(1):314-327. PubMed ID: 34718949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes.
    Kelsey MD; Mulder H; Chiswell K; Lampron ZM; Nilles E; Kulinski JP; Joshi PH; Jones WS; Chamberlain AM; Leucker TM; Hwang W; Milks MW; Paranjape A; Obeid JS; Linton MF; Kent ST; Peterson ED; O'Brien EC; Pagidipati NJ
    Am J Prev Cardiol; 2023 Jun; 14():100478. PubMed ID: 37025553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States.
    Baum SJ; Rane PB; Nunna S; Habib M; Philip K; Sun K; Wang X; Wade RL
    Am J Prev Cardiol; 2021 Jun; 6():100177. PubMed ID: 34327500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.
    Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Gao Q; Palagashvilli T; Alam S; Mues KE; Bhatt DL; Kosiborod MN;
    JAMA Cardiol; 2021 Sep; 6(9):1060-1068. PubMed ID: 34132735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease.
    Nissen SE; Wolski K; Cho L; Nicholls SJ; Kastelein J; Leitersdorf E; Landmesser U; Blaha M; Lincoff AM; Morishita R; Tsimikas S; Liu J; Manning B; Kozlovski P; Lesogor A; Thuren T; Shibasaki T; Matei F; Silveira FS; Meunch A; Bada A; Vijan V; Bruun NE; Nordestgaard BG;
    Open Heart; 2022 Oct; 9(2):. PubMed ID: 36252994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: A 2019 update.
    Gu J; Sanchez R; Chauhan A; Fazio S; Wong N
    Am J Prev Cardiol; 2022 Jun; 10():100336. PubMed ID: 35368909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients.
    Chen CC; Rane PB; Hines DM; Patel J; Harrison DJ; Wade RL
    Ther Clin Risk Manag; 2018; 14():2425-2435. PubMed ID: 30587999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
    Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
    Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.
    Navar AM; Kolkailah AA; Gupta A; Gillard KK; Israel MK; Wang Y; Peterson ED
    Circ Cardiovasc Qual Outcomes; 2023 Aug; 16(8):533-543. PubMed ID: 37529931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study).
    Binbrek AS; Elis A; Al-Zaibag M; Eha J; Keber I; Cuevas AM; Mukherjee S; Miller TR;
    Curr Ther Res Clin Exp; 2006 Jan; 67(1):21-43. PubMed ID: 24936119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience.
    Anastasiou G; Sakka E; Blathra E; Kalivi A; Elisaf M; Liamis G; Liberopoulos E
    Arch Med Res; 2021 May; 52(4):397-404. PubMed ID: 33380360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.